This data comes from a randomized, international, double blind study comparing LY-CoV555 to standard of care for the primary outcome of sustained recovery during a 90-day period in hospitalized patients with COVID-19, carried out in Fall 2020. Participants were randomized 1:1 to receive either Ly-CoV555 or matching placebo. All patients received high-quality supportive care as background therapy, including the use of remdesivir. A total of 314 patients were enrolled, 163 to LY-CoV555 and 151 to placebo. The rate ratio for sustained recovery was 1.06 (95% CI, 0.77 to 1.47).

Presence of Common Scales: No scales used. Primary endpoint was sustained recovery; discharged to home and remaining home for 14 consecutive days.

coded on-site observation; face-to-face interview; other; telephone interview; SAS datasets and item documentation

Response Rates: Response rate was not collected. Only participants that consented had data collected.

COVID-19 hospitalized patients age 18 and over. Smallest Geographic Unit: person level

Hospitalized patients with COVID-19

No weights used